Gregory Czarnota

Biography

Gregory Czarnota currently working as Associate Professor PhD, University of Toronto, Sunnybrook Health Sciences Centre 2075 Bayview Avenue, Room T2 167, Toronto, Ontario M4N 3M5. His research is centered on understanding how radiation affects blood vessels and how this contributes to tumour death. We have developed a number of small animal micro-ultrasound methods in our laboratory to detect vascular changes and separately apoptotic cell death in vivo. A number of different research projects are underway to study the basic science behind vascular responses to radiation and to therapeutically exploit this in order to radiosensitize tumours. In that regard our research interests include the novel use of pharmacologic anti-angiogenic agents and new ultrasound-activated anti-angiogenic agents. Gregory Czarnota currently working as Associate Professor PhD, University of Toronto, Sunnybrook Health Sciences Centre 2075 Bayview Avenue, Room T2 167, Toronto, Ontario M4N 3M5. His research is centered on understanding how radiation affects blood vessels and how this contributes to tumour death. We have developed a number of small animal micro-ultrasound methods in our laboratory to detect vascular changes and separately apoptotic cell death in vivo. A number of different research projects are underway to study the basic science behind vascular responses to radiation and to therapeutically exploit this in order to radiosensitize tumours. In that regard our research interests include the novel use of pharmacologic anti-angiogenic agents and new ultrasound-activated anti-angiogenic agents.

Research Interest

Our research is centered on understanding how radiation affects blood vessels and how this contributes to tumour death. We have developed a number of small animal micro-ultrasound methods in our laboratory to detect vascular changes and separately apoptotic cell death in vivo. A number of different research projects are underway to study the basic science behind vascular responses to radiation and to therapeutically exploit this in order to radiosensitize tumours. In that regard our research interests include the novel use of pharmacologic anti-angiogenic agents and new ultrasound-activated anti-angiogenic agents.